Other languages Aura Biosciences, Inc.

Equities

AURA

US05153U1079

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-14 EDT			5-day change	1st Jan Change
7.53 ^USD	+4.87%		+0.53%	-15.01%

05-09	Aura Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-15	Raj Parekh to Resign as Member of the Board of Directors of Aura Biosciences, Inc., Effective June 20, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Aura Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09
Raj Parekh to Resign as Member of the Board of Directors of Aura Biosciences, Inc., Effective June 20, 2024	04-15
Aura Biosciences Shares Rise Following Q4 Results	03-27
Aura Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-27
Arix Bioscience's Portfolio Company Doses First Patient in Late-stage Trial of Choroidal Melanoma Therapy	12-08
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-Sar) for First-Line Treatment of Early-Stage Choroidal Melanoma	12-07
Aura Biosciences Insider Bought Shares Worth $1,434,987, According to a Recent SEC Filing	11-09
Aura Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09
Aura Biosciences, Inc. Receives FDA Agreement Under Special Protocol Assessment for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-Sar) in Early-Stage Choroidal Melanoma	11-06
Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023	23-10-31
Aura Biosciences Insider Bought Shares Worth $168,175, According to a Recent SEC Filing	23-10-06
Aura Biosciences, Inc. Announces Executive Changes	23-10-02
Aura Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09
Aura Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11
Aura Biosciences, Inc. Announces Resignation of Mark De Rosch as Chief Operating Officer, Effective April 30, 2023	23-04-04
Aura Biosciences, Inc. Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration At the Macula Society 46Th Annual Meeting	23-02-16
Aura Biosciences Prices $80.4 Million Common Stock Offering	22-12-01
Aura Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10
Aura Announces Inc. Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma	22-11-10
Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Au-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented At Aao 2022	22-10-03

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Aura Biosciences, Inc.

Equities

AURA

US05153U1079

Other languages

Filters